The action of benzbromarone in relation to age, sex and accompanying diseases.
The uric-acid lowering effect was investigated in a group of 2220 patients. 1984 of these were employed for statistical evaluation purposes. On average, the uric acid level was reduced from 8,24 +/- 1,16 mg/100 ml to 5,32 +/- 1,265 mg/100 ml. In 82 % of all the cases, the uric acid level at the end of the treatment period was below 6,4 mg%, both in patients treated throughout with 50 mg benzbromarone (NarcaricinRmite) and in those changed over to 100 mg benzbromarone (NarcaricinR) after 1 to 3 weeks. The lowering of the uric acid levels was in no way related to hypertension, adiposity, hyperlipoproteinaemia, diabetes mellitus or age.
D001553:Benzbromarone / Q000009:adverse effects / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D001827:Body Height; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006073:Gout / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D014527:Uric Acid / Q000097:blood
D001572:Benzofurans; D014527:Uric Acid; D001553:Benzbromarone